News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
66,481 Results
Type
Article (5568)
Company Profile (17)
Press Release (60896)
Section
Business (25184)
Career Advice (156)
Deals (4258)
Drug Delivery (41)
Drug Development (6433)
Employer Resources (18)
FDA (1178)
Job Trends (1669)
News (35853)
Policy (2211)
Tag
Academia (279)
Alliances (6088)
Alzheimer's disease (224)
Antibody-drug conjugate (ADC) (14)
Approvals (1168)
Artificial intelligence (27)
Bankruptcy (34)
Best Places to Work (1247)
Biotechnology (16)
Breast cancer (14)
Cancer (95)
Cardiovascular disease (17)
Career advice (126)
Cell therapy (27)
Clinical research (4796)
Collaboration (56)
COVID-19 (326)
C-suite (18)
Data (79)
Diabetes (60)
Diagnostics (614)
Drug pricing (33)
Earnings (5271)
Employer resources (16)
Events (6213)
Executive appointments (62)
FDA (1211)
Funding (156)
Gene therapy (29)
GLP-1 (343)
Government (332)
Healthcare (1526)
Infectious disease (333)
Inflammatory bowel disease (20)
Interviews (24)
IPO (1943)
Job creations (461)
Job search strategy (120)
Layoffs (59)
Legal (506)
Lung cancer (17)
Manufacturing (41)
Medical device (1301)
Medtech (1303)
Mergers & acquisitions (2328)
Metabolic disorders (215)
Neuroscience (248)
NextGen Class of 2024 (1057)
Non-profit (367)
Northern California (168)
Now hiring (14)
Obesity (145)
Opinion (81)
People (10172)
Phase I (1492)
Phase II (1995)
Phase III (1799)
Pipeline (29)
Podcasts (25)
Policy (24)
Postmarket research (239)
Preclinical (680)
Radiopharmaceuticals (37)
Rare diseases (23)
Real estate (656)
Regulatory (1506)
Research institute (209)
Resumes & cover letters (22)
Series A (40)
Series B (34)
Southern California (112)
Startups (2197)
The Weekly (23)
United States (1107)
Vaccines (31)
Venture capitalists (18)
Weight loss (155)
Date
Today (21)
Last 7 days (84)
Last 30 days (331)
Last 365 days (3810)
2024 (3440)
2023 (3811)
2022 (6594)
2021 (5996)
2020 (5679)
2019 (5196)
2018 (4048)
2017 (3584)
2016 (3004)
2015 (3426)
2014 (2467)
2013 (2092)
2012 (2191)
2011 (2445)
2010 (2470)
Location
Africa (92)
Asia (4886)
Australia (576)
California (329)
Canada (285)
China (48)
Connecticut (17)
Europe (9418)
Florida (19)
Illinois (34)
Indiana (95)
Maryland (34)
Massachusetts (208)
New Jersey (44)
New York (73)
North Carolina (49)
Northern California (168)
Ohio (33)
Pennsylvania (38)
South America (125)
Southern California (112)
Texas (35)
Washington State (20)
66,481 Results for "lilly ventures".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug shortages
Lilly’s Tirzepatide Could Land Again on FDA Drug Shortage List, Opens Door for Compounders
While the regulator conducts another review into the supply of Eli Lilly’s tirzepatide, compounders will be able to continue selling their own remixed versions of the blockbuster drug.
October 14, 2024
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage Showing
Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop in the biomarker after 12 weeks.
November 19, 2024
·
2 min read
·
Tristan Manalac
Editorial
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.
November 1, 2024
·
3 min read
·
Greg Slabodkin
Obesity
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs
Eli Lilly CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as biotechs press on with compelling data.
October 9, 2024
·
3 min read
·
Annalee Armstrong
Inflammatory bowel disease
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting better long-term outcomes than Johnson & Johnson’s blockbuster therapy Stelara.
October 15, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Lilly Lowers Brain Swelling With Modified Dosing of Alzheimer’s Drug Kisunla
Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain swelling of patients in a late-stage trial following an adjusted dosing regimen.
October 30, 2024
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated steatohepatitis victory for Novo Nordisk’s Wegovy, growing excitement about CAR Ts for autoimmune disease and the ongoing controversy over HeLa cells.
November 6, 2024
·
1 min read
·
Heather McKenzie
Supply chain
Lilly’s Tirzepatide No Longer on FDA Drug Shortage List
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes and weight loss drugs are gaining market share as manufacturing continues to expand, while noting the drugmaker could start to benefit heading into third quarter earnings.
October 3, 2024
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly to Invest $4.5B in New Indiana Manufacturing and R&D Center
Eli Lilly’s investment in the LEAP Research and Innovation District in Lebanon, Indiana, has now jumped to more than $13 billion.
October 2, 2024
·
2 min read
·
Tristan Manalac
Editorial
Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?
Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s rival drugs, is not fair.
September 27, 2024
·
3 min read
·
Greg Slabodkin
1 of 6,649
Next
